Jubilant's Q3 sales flat but order book healthy
This article was originally published in Scrip
Executive Summary
Jubilant Life Sciences, India's largest custom research and manufacturing services company, has reported a marginal rise in net sales for the third quarter ended 31 December, to Rs8.67 billion ($193.9 million), compared with Rs8.65 billion from the same line of business prior to a restructuring last year.